XOMA

Ligand to acquire XOMA Royalty The Pharma Letter

Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal Investor's Business Daily

Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million Reuters

Ligand snaps up fellow biotech royalty aggregator Xoma for $739M Fierce Pharma

XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders Business Wire

Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million WSJ

Ligand to Acquire XOMA Royalty, Further Accelerating Profit GlobeNewswire

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator Stock Titan

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA PR Newswire NEW YORK, Jan. 22, 2026 NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomeran